FDA Generic Peptides Guidance Sets New Expectations

The FDA generic peptide guidance was updated with a more detailed regulatory pathway for manufacturers seeking approval of generic versions of complex peptide medicines.

The 28 July 2026 update covers 17 revised draft product-specific guidances and it introduces updated expectations for how applicants demonstrate sameness, quality, and therapeutic equivalence. 

Image

FDA Generic Peptide Guidance Expands Scope

The U.S. Food and Drug Administration (FDA) published revised draft product-specific guidances (PSGs) for 17 peptide products, including semaglutide, tirzepatide, liraglutide, glucagon, teriparatide, pegcetacoplan, and vosoritide.

Several are medicines used in areas including obesity, type 2 diabetes, osteoporosis, and macular degeneration.

The timing is hugely significant. Peptides are a really growing and important part of the pharmaceutical market, while demand for generic competition is increasing.

The FDA uses PSGs to give generic developers product-specific recommendations for abbreviated new drug applications (ANDAs).

The objective is to make development and regulatory review more predictable while ensuring generics meet the required standards for safety, effectiveness, quality, and therapeutic equivalence. 

However, this specific update really matters beyond the individual products listed.

Five Areas for Peptides Now Matter More

The revised PSGs update FDA recommendations across five areas:

• Manufacturing origin: Applicants can address peptides produced recombinantly, synthetically, or semi-synthetically through an ANDA where the applicable recommendations support that route.
• Innate immune response: Developers may need to assess whether differences between products could trigger an unwanted immune response.
• Impurities: The FDA provides updated expectations around impurity thresholds and characterisation.
• Higher-order structure: Applicants need to consider structural characteristics beyond basic sequence and composition.
• Biological activity: Developers need evidence that the proposed generic performs appropriately from a biological perspective.

The shift is important because peptide sameness cannot always be reduced to confirming an amino acid sequence.

The FDA’s earlier synthetic peptide guidance already recognised that manufacturing processes can produce peptide-related impurities involving amino acid sequence or residue changes, with potential implications for immunogenicity, safety, or effectiveness. 

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

FDA Generic Peptide Guidance Centralises Quality of Evidence 

For generic peptide developers, the revised FDA approach places greater emphasis on demonstrating that a proposed product is sufficiently comparable to its reference listed drug.

That means regulatory strategy must connect manufacturing process, analytical characterisation, impurity control, structural assessment, and biological performance.

What matters for development teams is that analytical methods cannot be treated as a final submission exercise. They need to support the evidence package throughout development.

The approach also reflects a wider FDA trend towards more scientifically specific regulatory frameworks. Pharmatica’s analysis of the FDA gene editing guidance examined a similar move towards clearer technical expectations for advanced therapies.

GLP-1 Generics Face Particular Attention

The inclusion of semaglutide and tirzepatide makes the update especially significant.

These medicines have become major products in obesity and metabolic disease, creating substantial commercial interest in future generic competition.

The revised PSGs cover both Ozempic and Wegovy for semaglutide, and Mounjaro and Zepbound for tirzepatide.

An FDA workshop on the generic GLP-1 pathway is also planned for September 2026. The programme will address critical quality attributes, manufacturing considerations, evidence for recombinant and synthetic generic peptides, and drug-device combination products. 

The FDA Retires an Older Peptide Framework

The agency is also withdrawing its May 2021 guidance on ANDAs (Abbreviated New Drug Applications) for certain highly purified synthetic peptide products that refer to listed drugs of recombinant DNA origin.

The FDA says that guidance no longer reflects its current scientific thinking and plans to revise it during 2026. That is more than an administrative change.

The draft guidance shows that the FDA is actively updating its peptide framework as scientific understanding, manufacturing technologies, and global regulatory approaches evolve.

Pharmatica has tracked a similar pattern in the FDA’s broader regulatory modernisation agenda, including its drug manufacturing registration proposals, where regulatory requirements are being reconsidered alongside changes in manufacturing technology and supply chains.

What Generics and Peptide Developers Should Watch from the FDA

The FDA is raising the level of scientific detail expected when demonstrating that generic peptide products are equivalent to their reference products.

That could improve regulatory predictability while also making high-quality analytical, structural, impurity, and biological and clinical evidence increasingly important to competitive generic development.

The revised draft PSGs are not final regulations. The FDA will consider comments before finalising them.

The agency also says that recommendations may be relevant to other generic peptide products, with developers encouraged to engage the Office of Generic Drugs through formal meetings or controlled correspondence where appropriate. 

For the industry, the immediate priority is therefore regulatory readiness rather than assuming final requirements.

Teams developing generic peptides should monitor the final PSGs, assess their analytical and manufacturing strategies against the revised recommendations, and engage regulators early where product-specific questions remain.

At Pharmatica, we track the regulatory systems shaping pharmaceutical development, manufacturing, and commercialisation. Our Insights connect FDA policy, scientific evidence, and industry strategy so decision-makers can understand where regulatory change creates new opportunities and requirements.

Pharmatica: Insight. Connection. Impact.

Image